Roctavian is an adeno-associated virus vector-based gene therapy that is administered as a single dose by intravenous infusion, according to a June 29 agency news release. It contains a viral vector carrying a gene for clotting, which is expressed in the liver to increase blood levels of factor VIII, a protein that enables blood clots, and reduces risk of uncontrolled bleeding.
In a trial of 112 patients with a three-year follow-up, the mean annual bleeding rate decreased from 5.4 bleeds per year to 2.6 bleeds.
Hemophilia A is a rare genetic bleeding disorder due to a mutation of the gene that produces factor VIII.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
